摘要
目的探讨布地奈德、特布他林、异丙托溴胺雾化联合甲强龙治疗支气管哮喘急性重症发作时的疗效情况。方法分析我院2013年2月~2014年4月收治的96例患者的临床资料,依据治疗方式不同进行分组,对照组46例和观察组50例。观察两组支气管哮喘急性重症发作患者临床症状消失时间、治疗前后肺功能、临床疗效情况。结果观察组支气管哮喘急性重症发作患者呼吸困难、喘息、啰音、咳嗽消失时间均低于对照组,差异有统计学意义(P<0.05)。两组支气管哮喘急性重症发作患者治疗前第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、最大呼气流速峰值(PEF)差异均无统计学意义(P>0.05),治疗后对照组和观察组患者FEV1、FVC、PEF均高于治疗前,观察组患者治疗后FEV1、FVC、PEF均高于对照组,观察组患者临床治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论布地奈德、特布他林、异丙托溴胺联用雾化并联合甲强龙治疗支气管哮喘急性重症发作患者,临床症状和肺功能改善明显,疗效良好,值得临床推广应用。
Objective To explore the effect of budesonide, terbutaline and ipratrominum bromide atomization combined with methylprednisolone in the treatment of acute severe attack of bronchial asthma. Methods The clinical data of 96 patients treated in our hospital from February 2013 to April 2014 were analyzed. According to the different treatment methods, they were divided into groups, with 46 cases in the control group and 50 cases in the observation group. The time of disappearance of clinical symptoms, lung function, and clinical efficacy before and after treatment were observed in the two groups of acute severe attack of bronchial asthma.Results The time of dyspnea, wheezing, rales and cough disappeared in the observation group was significantly lower than that in the control group, P < 0.05, the difference was statistically significant. There was no significant difference in the volume of forced expiratory volume(FEV1), forced vital capacity(FVC) and maximal expiratory flow rate(PEF) in the two groups of patients with severe acute exacerbation of asthma before treatment(P > 0.05). After treatment, the FEV1, FVC and PEF of the two groups were all higher than those before treatment. The FEV1, FVC and PEF of the observation group were all higher than those of the control group after treatment. The total effective rate of the observation group was higher than that of the control group, P < 0.05, the difference was statistically significant. Conclusion Budesonide, terbutaline and ipratrominum bromide atomization combined with methylprednisolone in the treatment of severe acute exacerbation of bronchial asthma has obvious improvement in clinical symptoms and pulmonary function, and the curative effect is good, so it is worthy of clinical application.
出处
《中国医药科学》
2018年第3期79-82,共4页
China Medicine And Pharmacy
